



Health Canada Issues Decision on Tesamorelin

March 4, 2013

Theratechnologies Inc. (TSX : TH) today announced that the Therapeutic Products Directorate of Health Canada has issued today a Notice of Non-compliance-Withdrawal (NON/w) for its New Drug Submission (NDS) for tesamorelin proposed for the treatment of excess abdominal fat in HIV-infected patients with lipodystrophy.